Twist Bioscience Co. (NASDAQ:TWST – Free Report) – Equities researchers at William Blair issued their Q1 2024 earnings estimates for shares of Twist Bioscience in a note issued to investors on Monday, November 20th. William Blair analyst M. Larew anticipates that the company will post earnings per share of ($0.82) for the quarter. The consensus estimate for Twist Bioscience’s current full-year earnings is ($3.73) per share. William Blair also issued estimates for Twist Bioscience’s Q2 2024 earnings at ($0.79) EPS and Q3 2024 earnings at ($0.78) EPS.
Several other brokerages have also recently issued reports on TWST. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $18.00 to $27.00 in a research note on Monday, August 7th. Barclays boosted their price target on shares of Twist Bioscience from $20.00 to $26.00 and gave the stock an “overweight” rating in a research note on Monday, August 7th. Finally, Berenberg Bank assumed coverage on shares of Twist Bioscience in a research report on Wednesday, September 27th. They issued a “buy” rating and a $27.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and a consensus target price of $28.43.
Twist Bioscience Trading Up 3.0 %
NASDAQ:TWST opened at $24.74 on Tuesday. The stock’s 50 day simple moving average is $18.72 and its 200-day simple moving average is $19.20. Twist Bioscience has a 12-month low of $11.46 and a 12-month high of $31.51. The firm has a market cap of $1.42 billion, a P/E ratio of -6.69 and a beta of 1.32.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last released its quarterly earnings results on Friday, November 17th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. The firm had revenue of $66.95 million for the quarter, compared to analyst estimates of $63.35 million. Twist Bioscience had a negative return on equity of 29.09% and a negative net margin of 88.97%. The business’s revenue was up 16.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.91) earnings per share.
Institutional Trading of Twist Bioscience
Several hedge funds and other institutional investors have recently made changes to their positions in TWST. BlackRock Inc. increased its holdings in Twist Bioscience by 11.1% in the second quarter. BlackRock Inc. now owns 6,905,031 shares of the company’s stock valued at $141,277,000 after buying an additional 691,590 shares in the last quarter. State Street Corp raised its holdings in Twist Bioscience by 19.2% during the first quarter. State Street Corp now owns 5,275,841 shares of the company’s stock worth $79,560,000 after purchasing an additional 849,592 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Twist Bioscience by 26.6% during the second quarter. JPMorgan Chase & Co. now owns 5,136,126 shares of the company’s stock worth $105,085,000 after purchasing an additional 1,078,814 shares in the last quarter. Capital World Investors grew its holdings in Twist Bioscience by 6.0% in the first quarter. Capital World Investors now owns 4,795,848 shares of the company’s stock valued at $236,819,000 after purchasing an additional 273,148 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Twist Bioscience by 10.8% in the first quarter. Vanguard Group Inc. now owns 4,791,074 shares of the company’s stock valued at $236,584,000 after buying an additional 467,466 shares in the last quarter.
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
- Five stocks we like better than Twist Bioscience
- Stock Dividend Cuts Happen Are You Ready?
- The most upgraded stocks in November have two things in common
- Best Aerospace Stocks Investing
- Monday.com rocked earnings like it’s the weekend
- How and Why to Invest in Oil Stocks
- Plan to own one retailer? Make it this one
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.